Enliven Therapeutics, Inc.

NasdaqGS ELVN

Enliven Therapeutics, Inc. Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending September 30, 2024: USD -1.53

Enliven Therapeutics, Inc. Free Cash Flow Per Share is USD -1.53 for the Trailing 12 Months (TTM) ending September 30, 2024, a 19.70% change year over year. Free cash flow per share is the free cash flow generated per share. Indicates investment potential based on cash flow generation.

Enliven Therapeutics, Inc. Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -1.90, a 59.81% change year over year.
Enliven Therapeutics, Inc. Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -4.73, a 45.99% change year over year.
Enliven Therapeutics, Inc. Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -8.76, a -0.69% change year over year.
Enliven Therapeutics, Inc. Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -8.70.

Key data

Date	Free Cash Flow Per Share	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)

NasdaqGS: ELVN

Enliven Therapeutics, Inc.

CEO	Mr. Samuel S. Kintz M.B.A.
IPO Date	March 12, 2020
Location	United States
Headquarters	6200 Lookout Road
Employees	46
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.

Key trends

Past 5 years